• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong.

作者信息

Koufakis Theocharis, Popovic Djordje S, Metallidis Symeon, Kotsa Kalliopi

机构信息

Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.

Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Novi Sad, Serbia; Medical Faculty, University of Novi Sad, Novi Sad, Serbia.

出版信息

Metabolism. 2022 Aug;133:155221. doi: 10.1016/j.metabol.2022.155221. Epub 2022 May 26.

DOI:10.1016/j.metabol.2022.155221
PMID:35644415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9132782/
Abstract
摘要

相似文献

1
COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong.2019冠状病毒病与磺脲类药物：在一类老牌药物即将退出历史舞台之际，对其多效性作用的一次提醒。
Metabolism. 2022 Aug;133:155221. doi: 10.1016/j.metabol.2022.155221. Epub 2022 May 26.
2
[40 years of using sulfonylurea derivatives for treatment of diabetes].使用磺脲类衍生物治疗糖尿病40年
Przegl Lek. 1996;53(9):641-6.
3
Do sulfonylureas influence hepatic insulin clearance?磺脲类药物会影响肝脏对胰岛素的清除吗？
Diabetes Care. 1988 Sep;11(8):689-90. doi: 10.2337/diacare.11.8.689.
4
Mechanisms and Characteristics of Sulfonylureas and Glinides.磺酰脲类和格列奈类的作用机制和特点。
Curr Top Med Chem. 2020;20(1):37-56. doi: 10.2174/1568026620666191224141617.
5
[Sulfonylureas and diabetes mellitus].
Med Clin (Barc). 1983 Sep 17;81(7):302-4.
6
[Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra].
Dtsch Med Wochenschr. 2011 Mar;136(11):547. doi: 10.1055/s-0031-1272566. Epub 2011 Feb 24.
7
Actual problems of the hypoglycaemic sulfonylureas.降血糖磺脲类药物的实际问题。
Ther Hung. 1977;25(2):47-50.
8
Sulfonylureas.磺脲类药物。
J Pak Med Assoc. 2015 Jan;65(1):101-4.
9
The role of glimepiride in the treatment of type 2 diabetes mellitus.格列美脲在 2 型糖尿病治疗中的作用。
Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):225-35. doi: 10.1517/17425250903512955.
10
[Molecular basis of oral hypoglycemic sulfonylurea action].[口服降糖磺脲类药物作用的分子基础]
Pol Merkur Lekarski. 2003 Nov;15(89):445-8.

引用本文的文献

1
Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory Study.无感染糖尿病患者的前降钙素原水平：一项探索性研究。
Biomedicines. 2024 Aug 29;12(9):1960. doi: 10.3390/biomedicines12091960.
2
Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic.抗糖尿病药物在降低 COVID-19 大流行期间死亡率方面的疗效。
Medicina (Kaunas). 2023 Oct 11;59(10):1810. doi: 10.3390/medicina59101810.
3
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.细胞色素 P450 2C9 在 COVID-19 治疗中的作用：现状与未来方向。
Eur J Drug Metab Pharmacokinet. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8. Epub 2023 Apr 24.

本文引用的文献

1
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.新冠病毒的免疫特征：细胞因子风暴的深入原因及后果。
Int J Mol Sci. 2022 Apr 20;23(9):4545. doi: 10.3390/ijms23094545.
2
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.COVID-19 合并 2 型糖尿病患者入院前使用降糖药物与死亡率的meta 分析
Metabolism. 2022 Jun;131:155196. doi: 10.1016/j.metabol.2022.155196. Epub 2022 Mar 31.
3
Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.2 型糖尿病合并 COVID-19 患者应用抗糖尿病药物的死亡风险：一项系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 Sep 16;12:708494. doi: 10.3389/fendo.2021.708494. eCollection 2021.
4
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.抗糖尿病药物与糖尿病患者 COVID-19 临床结局的关联：系统评价和荟萃分析。
Arch Med Res. 2022 Feb;53(2):186-195. doi: 10.1016/j.arcmed.2021.08.002. Epub 2021 Aug 9.
5
Cardiovascular risk and complications associated with COVID-19.与新型冠状病毒肺炎相关的心血管风险及并发症
Am J Cardiovasc Dis. 2020 Oct 15;10(4):479-489. eCollection 2020.
6
Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study.糖尿病、血糖控制与 COVID-19 住院风险：基于人群的前瞻性队列研究。
Metabolism. 2020 Nov;112:154344. doi: 10.1016/j.metabol.2020.154344. Epub 2020 Aug 22.
7
A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?房间里的一头狮子：卡罗来纳州试验是否已明确解决了磺脲类药物心血管安全性的问题？
J Diabetes. 2020 Jul;12(7):499-502. doi: 10.1111/1753-0407.13035. Epub 2020 Mar 23.
8
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.利格列汀与格列美脲对2型糖尿病患者主要不良心血管结局的影响：卡罗来纳州随机临床试验
JAMA. 2019 Sep 24;322(12):1155-1166. doi: 10.1001/jama.2019.13772.
9
NLRP3 inflammasome inhibitor glyburide expedites diabetic-induced impaired fracture healing.NLRP3 炎性小体抑制剂格列吡嗪加速糖尿病诱导的骨折愈合受损。
Immunobiology. 2019 Nov;224(6):786-791. doi: 10.1016/j.imbio.2019.08.008. Epub 2019 Aug 23.
10
Diabetes medications: Impact on inflammation and wound healing.糖尿病药物：对炎症和伤口愈合的影响。
J Diabetes Complications. 2016 May-Jun;30(4):746-52. doi: 10.1016/j.jdiacomp.2015.12.017. Epub 2015 Dec 19.